Aflibercept in Clinical Practice
Authors:
J. Bajaček; A. Bieliková
Authors place of work:
Oftalmologická klinika, Ústredná vojenská nemocnica SNP-FN, Ružomberok, prednostka kliniky MUDr. Bieliková Anna, PhD.
Published in the journal:
Čes. a slov. Oftal., 71, 2015, No. 2, p. 101-108
Category:
Original Article
Summary
In this article we have tried to evaluate first clinical experience with the effectiveness and safety of aflibercept in the treatment of the wet form of age related macular degeneration in all types of subretinal neovascular membranes for the period of the first 10 months of treatment in our clinic.
Key words:
aflibercept, wet age related macular degeneration, subretinal neovascular membrane
Zdroje
1. Bressler, S.B., Bressler, N.M., Fine, S.L. et al.: Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol, 93(2); 1982: 157–163.
2. Congdon, N., O’Colmain, B., Klaver, C.C. et al.: Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol, 122 (4); 2014: 477–485.
3. Heier, J.S., Brown, M.D., Chong, V. et al.: Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology, 119 (12); 2012: 2537–2548.
4. Chang, A.A., Li, H., Broadhead, G.K. et al.: Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology, 121; 2014: 188–192.
5. Cho, H., Weber, M.L., Shah, C.P. et al.: Initial utilization of aflibercept in exudative age related macular degeneration. Eur J Ophthalmol, 24(4); 2014: 576–581.
6. Martin, D.F., Maguire, M.G., Ying, G.S. et al: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med, 364(20); 2011: 1897–1908.
7. Papadopoulos, N., Martin, J., Ruan, Q. et al.: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15(2); 2012: 171–185.
8. Resnikoff, S., Pascolini, D., Etya’ale, D. et al.: Global data on visual impairment in the year 2002, Bull World Health Organ, 82(11); 2004: 844–851.
9. Rudge, J.S., Holash, J., Hylton, D. et al.: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A, 104(47); 2007: 18363–18370.
10. Sawa, Y. et al.: Short-term outcomes of aflibercept for recurrent neovascular age-related macular degeneration in Japanese patients. E-poster PO-1531, World Ophthalmology Congress 2014, Tokyo, Japan, April 2–6, 2014.
11. Schmidt-Erfurth, U. et al.: Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology, 121; 2014: 193–201.
12. Schmier, J.K., Jones, M.L., Halpern, M.T.: The burden of age-related macular degeneration. Pharmacoeconomics, 24(4); 2006: 319–334.
13. Soubrane, G., Cruess, A., Lotery, A. et al.: Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol, 125(9); 2007: 1249–1254.
14. Eylea (aflibercept injekčný roztok v liekovke) Súhrn charakteristických vlastností lieku. Berlin, Nemecko: Bayer Pharma AG: 2014.
15. Wykoff, C.C., Brown, D.M., Maldonado, M.E. et al.: Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol, 98(7); 2014: 951–955.
16. Yonekawa, Y., Andreoli, C., Miller, J.B. et al.: Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol, 156(1); 2013: 29–35.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2015 Číslo 2
Najčítanejšie v tomto čísle
- STORY of the Papilla - a Case Report
- Clinical Results after Continuous Corneal ring (MyoRing) Implantation in Keratoconus Patients
- Acute Zonal Occult Outer Retinopathy – a Case with Rapid Return of Visual Functions in Type 3 Disease
- Aflibercept in Clinical Practice